Medelis’ world-class medical and project teams have extensive experience in the design, performance and analysis of complex clinical trials. With this focus, we offer the seasoning and insight only long practice in complex studies can produce.
With our full-service offering, we can create and implement a detailed drug development plan carefully structured to address all regulatory needs and requirements. We’ll optimize the likely outcomes for your agent with respect to follow-on studies and additional indications, delivering maximum value for your clinical investment.
Our specialization in oncology CRO services provides clients with:
For sponsors looking for a true partner to trust throughout the oncology drug development process, Medelis provides:
Our team is accustomed to handling most targets in oncology. This portfolio of expertise means faster, more accurate results and more strategic long-term development planning.
Oncology studies can be complex. For immuno-oncology studies, there are an entirely different set of complexities that cause additional delays. Immuno-oncology is a promising area of research, with thousands of new studies launching each year. Medelis has been pioneering immunotherapy studies since 2008, running many CAR T-cell therapy studies, checkpoint inhibitor studies and bispecific antibody treatment studies.